SCHEMBL4900664

SCHEMBL4900664

COC(=O)c1cc2[c]ccc(C)c2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
XDH P47989 4/20 0.44
GAA P10253 3/20 0.42
GLA P06280 2/20 0.42
CYP1A2 P05177 1/20 0.41
KDM4E B2RXH2 2/20 0.37
NR4A2 P43354 1/20 0.36
ALPL P05186 2/20 0.36
MAPT P10636 2/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35
NGFR P08138 1/20 0.35
ABL1 P00519 2/20 0.35
SRC P12931 2/20 0.35
MAPK1 P28482 1/20 0.35
SYK P43405 1/20 0.34
NSD2 O96028 1/20 0.33
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4893982 0.84 GLA (0.41) XDHGAAGLACYP1A2KDM4E
SCHEMBL8318563 0.78 GLA (0.49) XDHGAAGLACYP1A2KDM4E
SCHEMBL4899112 0.74 XDH (0.45) XDHGAAGLACYP1A2KDM4E
SCHEMBL3283667 0.72 NSD2 (0.61) XDHGAAGLAKDM4ENR4A2
SCHEMBL4900806 0.71 KDM4E (0.41) GAAKDM4EMAPTPOLB
SCHEMBL10093729 0.71 GLA (0.46) XDHGAAGLACYP1A2KDM4E
SCHEMBL8324052 0.70 XDH (0.55) XDHGAAGLACYP1A2KDM4E
SCHEMBL8319614 0.70 GAA (0.62) XDHGAAGLACYP1A2KDM4E
SCHEMBL8320394 0.70 GLA (0.45) XDHGAAGLACYP1A2KDM4E
SCHEMBL8322220 0.70 GLA (0.45) XDHGAAGLACYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130331395-A1 BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2013-12-12 US claimed
US-8530475-B2 Serotonin reuptake inhibitors and antagonists of the serotonin 1A receptor; compounds are based on 7,9-diazabicyclo(4.2.2)dec-3-ene ring JANSSEN PHARMACEUTICA NV 2013-09-10 US claimed
US-20080070919-A1 BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS CREIGHTON CHRISTOPHER J 2008-03-20 US claimed
WO-2007137168-A2 BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-29 WO claimed
US-20130331395-A1 BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2013-12-12 US disclosed
US-8530475-B2 Serotonin reuptake inhibitors and antagonists of the serotonin 1A receptor; compounds are based on 7,9-diazabicyclo(4.2.2)dec-3-ene ring JANSSEN PHARMACEUTICA NV 2013-09-10 US disclosed
US-20080070919-A1 BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS CREIGHTON CHRISTOPHER J 2008-03-20 US disclosed
WO-2007137168-A2 BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070919-A1 BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS HTR1A, HTR5A, TPH1 XDH 1959/4885GAA 1552/4885GLA 3840/4885
US-20130331395-A1 BRIDGED ARYL PIPERAZINES DERIVATIVES USEFUL FOR THE TREATMENT OF CNS, GI-URINARY AND REPRODUCTIVE DISORDERS HTR1A, HTR5A, TPH1 XDH 1959/4885GAA 1552/4885GLA 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.